Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Small Cell Lung Cancer

Small Cell Lung Cancer

Part of Extensive-Stage Small-Cell Lung Cancer

20 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Small Cell Lung Cancer

61 trials tracked for Small Cell Lung Cancer: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 154 citations.

61Trials tracked
8Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 8 Phase 2 47 Phase 1 3 Other / NA 3
  1. Phase 3 Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 154 cited
  2. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 134 cited
  3. Phase 3 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Completed · 125 cited
  4. Phase 3 Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Completed · 124 cited
  5. Phase 3 A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 123 cited
  6. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 45 cited
Show 44 more trials
  1. Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Completed · 40 cited
  2. Phase 3 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed
  3. Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Completed
  4. Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Completed
  5. Phase 2 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed
  6. Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Completed
  7. Phase 2 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Completed
  8. Phase 2 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Completed
  9. Phase 2 Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Completed
  10. Phase 2 Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Completed
  11. Phase 2 Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer Completed
  12. Phase 2 A Study for Participants With Small-Cell Lung Cancer Completed
  13. Phase 2 Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed
  14. Phase 2 Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer Completed
  15. Phase 2 BMS-986012 in Relapsed/Refractory SCLC Completed
  16. Phase 2 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer Completed
  17. Phase 2 First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Completed
  18. Phase 2 Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer Completed
  19. Phase 2 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
  20. Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Completed
  21. Phase 2 Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer Completed
  22. Phase 2 Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma Completed
  23. Phase 2 Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer Completed
  24. Phase 2 Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Completed
  25. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  26. Phase 2 Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Completed
  27. Phase 2 Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Completed
  28. Phase 2 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Completed
  29. Phase 2 Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy Completed
  30. Phase 2 Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma Completed
  31. Phase 2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Completed
  32. Phase 2 A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) Completed
  33. Phase 2 A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Completed
  34. Phase 2 Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer Completed
  35. Phase 2 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Completed
  36. Phase 2 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Completed
  37. Phase 2 SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy Completed
  38. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Completed
  39. Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Completed
  40. Phase 2 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) Completed
  41. Phase 2 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer Completed
  42. Phase 2 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Completed
  43. Phase 2 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed
  44. Phase 2 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Small Cell Lung Cancer: what the trials found

Several agents have demonstrated statistically significant improvements in survival outcomes for Small Cell Lung Cancer. Tislelizumab showed a significant improvement in both Overall Survival (OS) and Progression Free Survival (PFS) compared to the control group 3. Similarly, Rovalpituzumab tesirine resulted in significantly improved OS and PFS 4, while pemetrexed demonstrated statistically significant improvements in OS across various subgroups 9.

Other interventions showed mixed or non-significant results regarding survival. Lurbinectedin (PM01183) did not show a statistically significant difference in OS compared to the control at 12 or 18 months 5. Tiragolumab also failed to reach statistical significance for both PFS and OS in primary analysis sets 6.

In terms of response rates, Irinotecan liposome injection showed a statistically significant improvement in Objective Response Rate (ORR) compared to the control, despite non-significant results for OS and PFS 8.

Recent results — preliminary, needs further review

  • NT-I7 was evaluated in a biomarker cohort regarding the percentage of area occupied by tumor-infiltrating lymphocytes (TILs) 1.
  • The combination of Olaparib plus EP0057 (CLRX101) showed a Progression Free Survival (PFS) rate of 2 at 16 weeks in an expansion cohort 10.

For the clinician treating this condition

  • Tislelizumab, Rovalpituzumab tesirine, and pemetrexed are associated with statistically significant improvements in OS or PFS.
  • Irinotecan liposome injection is associated with a significantly higher Objective Response Rate (ORR) compared to control groups.
  • Lurbinectedin and Tiragolumab did not demonstrate statistically significant improvements in survival outcomes in the reported trials.

AI synthesis of 8 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical
Oncology Sys. Review
Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypothetical Gut Health Links May Influence Lung Cancer Treatment Paths
This narrative review with a systematic search examined 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. Solub…
New research explores how the gut-lung axis and specific metabolites might play a role in managing lung cancer treatments.
Frontiers Sep 13, 2026
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
Oncology Sys. Review
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
Frontiers Sep 8, 2026
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer
Allergy & Immunology Meta-analysis
B7-H3-targeted ADCs achieve 54% objective response rate in previously treated small cell lung cancer B7-H3 Targeted Drugs Show Promise for Small Cell Lung Cancer
This systematic review and meta-analysis evaluates B7-H3-targeted antibody-drug conjugates for patients with previously treated small cell l…
New data suggests B7-H3 targeted therapies may offer higher response rates than standard treatments for patients with small cell lung cancer…
Frontiers Aug 13, 2026
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Oncology Sys. Review
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
NEJM Aug 9, 2026
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Allergy & Immunology Meta-analysis
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Frontiers Jul 22, 2026
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
Oncology Meta-analysis
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer Nab-paclitaxel shows similar results to paclitaxel for lung cancer
This meta-analysis examined paclitaxel monotherapy in relapsed small cell lung cancer. The 3-month progression-free survival rate was modest…
New data compares two types of paclitaxel treatments for relapsed small cell lung cancer, showing similar safety and effectiveness.
Jul 3, 2026
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Drug Pipeline Meta-analysis
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Frontiers Jun 13, 2026
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Pulmonology & Critical Care RCT
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Jun 7, 2026
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Allergy & Immunology Sys. Review
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Frontiers May 27, 2026
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Oncology Meta-analysis
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
May 5, 2026
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
Pulmonology & Critical Care Phase II
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
May 1, 2026
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Pulmonology & Critical Care Meta-analysis
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
May 1, 2026

Research across Extensive-Stage Small-Cell Lung Cancer

Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.

Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Oncology RCT
Ivonescimab Combined With Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC Trial shows ivonescimab plus chemotherapy improves lung cancer outcomes
Ivonescimab plus pemetrexed and carboplatin significantly extends progression-free survival for patients with advanced EGFR-mutated NSCLC.
A new treatment combination involving ivonescimab and chemotherapy showed a significant improvement in progression-free survival for certain…
Sep 10, 2026
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Oncology Meta-analysis
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors Bispecific antibodies improve survival for patients with solid tumors
This meta-analysis of 3505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR …
A new type of antibody treatment shows promise in extending life and slowing cancer growth for patients with solid tumors.
Sep 9, 2026
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC
Pulmonology & Critical Care RCT
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC Adding chemotherapy to osimertinib extends survival for specific lung cancer
This Phase 3 randomized clinical trial of 294 treatment-naive, stage IV or recurrent nonsquamous NSCLC patients with concurrent TP53 and EGF…
A new combination of osimertinib and chemotherapy significantly extends the time patients with specific lung cancer mutations live without d…
JAMA Sep 8, 2026
Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
Oncology Meta-analysis
Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression Adding Chemotherapy to Immune Therapy for Lung Cancer Shows Mixed Results
A meta-analysis of 3,252 patients reveals that adding chemotherapy to ICI monotherapy does not provide a consistent survival advantage.
New analysis suggests that adding chemotherapy to immunotherapy for certain lung cancers may not provide a consistent survival benefit over …
medRxiv Sep 6, 2026
EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
Oncology Sys. Review
EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases Combination therapies show promise for lung cancer with brain spread
This systematic review and network meta-analysis of 5432 patients with EGFR-mutated non-small cell lung cancer and brain metastases found th…
New data suggests that combining specific drugs can improve survival and slow cancer growth in patients with lung cancer that has spread to …
Sep 4, 2026
Robotic-assisted thoracoscopic segmentectomy results in lower intraoperative blood loss compared to video-assisted thoracoscopic segmentectomy
Pulmonology & Critical Care Meta-analysis
Robotic-assisted thoracoscopic segmentectomy results in lower intraoperative blood loss compared to video-assisted thoracoscopic segmentectomy Robotic surgery shows less blood loss for early lung cancer
This meta-analysis of propensity-matched studies included 14,007 patients with early-stage non-small cell lung cancer undergoing segmentecto…
Robotic surgery may reduce blood loss during lung cancer procedures while providing similar survival rates to traditional methods.
Sep 2, 2026
Durvalumab plus tremelimumab shows no significant overall survival benefit compared to durvalumab alone
Oncology Meta-analysis
Durvalumab plus tremelimumab shows no significant overall survival benefit compared to durvalumab alone Adding tremelimumab to durvalumab does not improve lung cancer survival
This meta-analysis of 2726 patients with metastatic non-small cell lung cancer found no significant overall survival benefit for durvalumab …
Combining two specific immunotherapies for metastatic lung cancer does not improve survival but significantly increases the risk of severe s…
Sep 2, 2026
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Oncology Sys. Review
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Frontiers Aug 27, 2026
iPSC-derived CAR-NK extracellular vesicles represent a translational hypothesis for non-small cell lung cancer
Oncology Sys. Review
iPSC-derived CAR-NK extracellular vesicles represent a translational hypothesis for non-small cell lung cancer New Research Explores Using Nanoscale Vesicles for Lung Cancer
This narrative review explores the use of iPSC-derived CAR-NK extracellular vesicles (EVs/sEVs) as an investigational platform for non-small…
Scientists are exploring how tiny vesicles from engineered cells might offer a safer way to deliver cancer treatments directly to lung tumor…
Frontiers Aug 27, 2026
Metabolic parameters MTV and TLG predict poorer survival in NSCLC patients on immune checkpoint inhibitors
Allergy & Immunology Meta-analysis
Metabolic parameters MTV and TLG predict poorer survival in NSCLC patients on immune checkpoint inhibitors Specific PET scan metrics predict outcomes for lung cancer patients
This systematic review and meta-analysis of 33 studies evaluated baseline [18F] FDG PET/CT metabolic parameters as prognostic indicators for…
Certain measurements from PET scans can help doctors predict how well lung cancer patients will respond to immune checkpoint inhibitor thera…
Frontiers Aug 25, 2026
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Drug Pipeline Sys. Review
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Frontiers Aug 23, 2026
Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations
Oncology RCT
Sunvozertinib improves progression-free survival in patients with advanced NSCLC and EGFR exon 20 mutations New drug shows promise for specific type of lung cancer
This trial compared sunvozertinib against carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC featuring EGFR exon 20 inse…
A new drug called sunvozertinib may help patients with a specific lung cancer mutation live longer without their tumors growing.
Aug 21, 2026

Questions about Small Cell Lung Cancer

Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?

Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.

Full answer →
Do bispecific antibodies or CAR T-cell therapy treat advanced Small Cell Lung Cancer?

Yes, both bispecific antibodies and CAR T-cell therapy are being studied for advanced SCLC, with bispecific antibodies showing more clinical progress, especially tarlatamab targeting DLL3.

Full answer →
Do immune checkpoint inhibitors improve survival for first-line Small Cell Lung Cancer treatment?

Yes, immune checkpoint inhibitors combined with chemotherapy improve survival as first-line treatment for extensive-stage small-cell lung cancer.

Full answer →

All Small Cell Lung Cancer Articles